TEVA PHARMACEUTICAL-SP ADR (TEVA) Fundamental Analysis & Valuation

NYSE:TEVA • US8816242098

Current stock price

28.74 USD
-1.04 (-3.49%)
At close:
28.7 USD
-0.04 (-0.14%)
After Hours:

This TEVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. TEVA Profitability Analysis

1.1 Basic Checks

  • TEVA had positive earnings in the past year.
  • In the past year TEVA had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: TEVA reported negative net income in multiple years.
  • TEVA had a positive operating cash flow in each of the past 5 years.
TEVA Yearly Net Income VS EBIT VS OCF VS FCFTEVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5B -10B -15B

1.2 Ratios

  • TEVA has a Return On Assets of 3.46%. This is amongst the best in the industry. TEVA outperforms 83.42% of its industry peers.
  • With an excellent Return On Equity value of 17.81%, TEVA belongs to the best of the industry, outperforming 90.16% of the companies in the same industry.
  • TEVA has a better Return On Invested Capital (12.03%) than 91.19% of its industry peers.
  • TEVA had an Average Return On Invested Capital over the past 3 years of 10.53%. This is below the industry average of 13.06%.
  • The 3 year average ROIC (10.53%) for TEVA is below the current ROIC(12.03%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROIC 12.03%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)10.53%
ROIC(5y)9.34%
TEVA Yearly ROA, ROE, ROICTEVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • TEVA's Profit Margin of 8.16% is amongst the best of the industry. TEVA outperforms 84.46% of its industry peers.
  • TEVA has a better Operating Margin (24.09%) than 91.71% of its industry peers.
  • In the last couple of years the Operating Margin of TEVA has grown nicely.
  • With a decent Gross Margin value of 52.72%, TEVA is doing good in the industry, outperforming 66.84% of the companies in the same industry.
  • TEVA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 24.09%
PM (TTM) 8.16%
GM 52.72%
OM growth 3Y3.96%
OM growth 5Y4.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
TEVA Yearly Profit, Operating, Gross MarginsTEVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. TEVA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TEVA is creating some value.
  • TEVA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for TEVA has been increased compared to 5 years ago.
  • Compared to 1 year ago, TEVA has an improved debt to assets ratio.
TEVA Yearly Shares OutstandingTEVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
TEVA Yearly Total Debt VS Total AssetsTEVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • Based on the Altman-Z score of 0.91, we must say that TEVA is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of TEVA (0.91) is comparable to the rest of the industry.
  • TEVA has a debt to FCF ratio of 14.64. This is a negative value and a sign of low solvency as TEVA would need 14.64 years to pay back of all of its debts.
  • The Debt to FCF ratio of TEVA (14.64) is better than 77.20% of its industry peers.
  • A Debt/Equity ratio of 1.90 is on the high side and indicates that TEVA has dependencies on debt financing.
  • TEVA's Debt to Equity ratio of 1.90 is on the low side compared to the rest of the industry. TEVA is outperformed by 76.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.9
Debt/FCF 14.64
Altman-Z 0.91
ROIC/WACC1.49
WACC8.06%
TEVA Yearly LT Debt VS Equity VS FCFTEVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • TEVA has a Current Ratio of 1.04. This is a normal value and indicates that TEVA is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of TEVA (1.04) is worse than 81.87% of its industry peers.
  • A Quick Ratio of 0.80 indicates that TEVA may have some problems paying its short term obligations.
  • TEVA's Quick ratio of 0.80 is on the low side compared to the rest of the industry. TEVA is outperformed by 80.83% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 0.8
TEVA Yearly Current Assets VS Current LiabilitesTEVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TEVA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 17.27% over the past year.
  • The Earnings Per Share has been growing slightly by 4.89% on average over the past years.
  • Looking at the last year, TEVA shows a small growth in Revenue. The Revenue has grown by 4.32% in the last year.
  • Measured over the past years, TEVA shows a small growth in Revenue. The Revenue has been growing by 0.71% on average per year.
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%

3.2 Future

  • Based on estimates for the next years, TEVA will show a small growth in Earnings Per Share. The EPS will grow by 6.00% on average per year.
  • Based on estimates for the next years, TEVA will show a small growth in Revenue. The Revenue will grow by 1.80% on average per year.
EPS Next Y-5.45%
EPS Next 2Y2.99%
EPS Next 3Y6%
EPS Next 5YN/A
Revenue Next Year-0.99%
Revenue Next 2Y0.75%
Revenue Next 3Y1.8%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TEVA Yearly Revenue VS EstimatesTEVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5B 10B 15B 20B
TEVA Yearly EPS VS EstimatesTEVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

8

4. TEVA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 9.78, the valuation of TEVA can be described as very reasonable.
  • Based on the Price/Earnings ratio, TEVA is valued cheaply inside the industry as 90.67% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 24.89, TEVA is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 10.34, the valuation of TEVA can be described as very reasonable.
  • Based on the Price/Forward Earnings ratio, TEVA is valued cheaper than 86.01% of the companies in the same industry.
  • TEVA is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 9.78
Fwd PE 10.34
TEVA Price Earnings VS Forward Price EarningsTEVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 89.12% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, TEVA is valued cheaply inside the industry as 81.87% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 29.16
EV/EBITDA 9.05
TEVA Per share dataTEVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • TEVA has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.99%
EPS Next 3Y6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TEVA Dividend Analysis

5.1 Amount

  • No dividends for TEVA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TEVA Fundamentals: All Metrics, Ratios and Statistics

TEVA PHARMACEUTICAL-SP ADR

NYSE:TEVA (3/27/2026, 8:04:00 PM)

After market: 28.7 -0.04 (-0.14%)

28.74

-1.04 (-3.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-28
Earnings (Next)05-05
Inst Owners20.99%
Inst Owner Change5.52%
Ins Owners0.45%
Ins Owner Change13.72%
Market Cap33.47B
Revenue(TTM)17.26B
Net Income(TTM)1.41B
Analysts82.86
Price Target0.11 (-99.62%)
Short Float %2.89%
Short Ratio3.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.53%
Min EPS beat(2)16.51%
Max EPS beat(2)38.54%
EPS beat(4)4
Avg EPS beat(4)16.39%
Min EPS beat(4)4.65%
Max EPS beat(4)38.54%
EPS beat(8)7
Avg EPS beat(8)8.31%
EPS beat(12)9
Avg EPS beat(12)5.55%
EPS beat(16)10
Avg EPS beat(16)3.14%
Revenue beat(2)2
Avg Revenue beat(2)3.32%
Min Revenue beat(2)0.9%
Max Revenue beat(2)5.75%
Revenue beat(4)2
Avg Revenue beat(4)-0.7%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)5.75%
Revenue beat(8)5
Avg Revenue beat(8)0.11%
Revenue beat(12)8
Avg Revenue beat(12)1.11%
Revenue beat(16)8
Avg Revenue beat(16)-0.59%
PT rev (1m)-1.91%
PT rev (3m)2.76%
EPS NQ rev (1m)2.03%
EPS NQ rev (3m)-6.41%
EPS NY rev (1m)-2.15%
EPS NY rev (3m)-1.31%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)-4.2%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)-1.5%
Valuation
Industry RankSector Rank
PE 9.78
Fwd PE 10.34
P/S 1.94
P/FCF 29.16
P/OCF 20.3
P/B 4.23
P/tB N/A
EV/EBITDA 9.05
EPS(TTM)2.94
EY10.23%
EPS(NY)2.78
Fwd EY9.67%
FCF(TTM)0.99
FCFY3.43%
OCF(TTM)1.42
OCFY4.93%
SpS14.82
BVpS6.79
TBVpS-10.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number21.2
Profitability
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROCE 15.24%
ROIC 12.03%
ROICexc 13.83%
ROICexgc 82.57%
OM 24.09%
PM (TTM) 8.16%
GM 52.72%
FCFM 6.65%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)10.53%
ROIC(5y)9.34%
ROICexc(3y)11.98%
ROICexc(5y)10.44%
ROICexgc(3y)70.07%
ROICexgc(5y)58.35%
ROCE(3y)13.34%
ROCE(5y)11.83%
ROICexgc growth 3Y24.16%
ROICexgc growth 5Y15.53%
ROICexc growth 3Y17.63%
ROICexc growth 5Y14.52%
OM growth 3Y3.96%
OM growth 5Y4.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
F-Score8
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 1.9
Debt/FCF 14.64
Debt/EBITDA 2.91
Cap/Depr 50%
Cap/Sales 2.9%
Interest Coverage 4.38
Cash Conversion 31.96%
Profit Quality 81.48%
Current Ratio 1.04
Quick Ratio 0.8
Altman-Z 0.91
F-Score8
WACC8.06%
ROIC/WACC1.49
Cap/Depr(3y)47.55%
Cap/Depr(5y)45.36%
Cap/Sales(3y)3.08%
Cap/Sales(5y)3.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
EPS Next Y-5.45%
EPS Next 2Y2.99%
EPS Next 3Y6%
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%
Revenue Next Year-0.99%
Revenue Next 2Y0.75%
Revenue Next 3Y1.8%
Revenue Next 5YN/A
EBIT growth 1Y17.36%
EBIT growth 3Y9.12%
EBIT growth 5Y5.49%
EBIT Next Year16.83%
EBIT Next 3Y11.69%
EBIT Next 5YN/A
FCF growth 1Y53.27%
FCF growth 3Y3.28%
FCF growth 5Y12.47%
OCF growth 1Y32.24%
OCF growth 3Y1.22%
OCF growth 5Y6.28%

TEVA PHARMACEUTICAL-SP ADR / TEVA Fundamental Analysis FAQ

What is the fundamental rating for TEVA stock?

ChartMill assigns a fundamental rating of 5 / 10 to TEVA.


What is the valuation status of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?

ChartMill assigns a valuation rating of 8 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.


Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?

TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 8 / 10.


What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?

The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 9.78 and the Price/Book (PB) ratio is 4.23.


What is the earnings growth outlook for TEVA PHARMACEUTICAL-SP ADR?

The Earnings per Share (EPS) of TEVA PHARMACEUTICAL-SP ADR (TEVA) is expected to decline by -5.45% in the next year.